Compugen Ltd. - Ordinary Shares (CGEN): Price and Financial Metrics


Compugen Ltd. - Ordinary Shares (CGEN)

Today's Latest Price: $16.30 USD

1.35 (-7.65%)

Updated Sep 23 4:00pm

Add CGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CGEN Daily Price Range
CGEN 52-Week Price Range

CGEN Stock Price Chart Technical Analysis Charts


CGEN Price/Volume Stats

Current price $16.30 52-week high $19.90
Prev. close $17.65 52-week low $3.83
Day low $16.24 Volume 1,836,799
Day high $17.52 Avg. volume 1,287,028
50-day MA $16.59 Dividend yield N/A
200-day MA $11.99 Market Cap 1.12B

Compugen Ltd. - Ordinary Shares (CGEN) Company Bio


Compugen Ltd. engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. The company was founded in 1993 and is headquartered in Tel Aviv, Israel.


CGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

CGEN Latest Social Stream


Loading social stream, please wait...

View Full CGEN Social Stream

Latest CGEN News From Around the Web

Below are the latest news stories about Compugen Ltd that investors may wish to consider to help them evaluate CGEN as an investment opportunity.

Our Take On Compugen's (NASDAQ:CGEN) CEO Salary

This article will reflect on the compensation paid to Anat Cohen-Dayag who has served as CEO of Compugen Ltd...

Yahoo | September 12, 2020

Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors

Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers Squibb’s (BMY) Opdivo and their investigational anti-TIGIT antibody-BMS-986207 for solid tumors.Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207.The study, which will initially enroll about 100 patients, will evaluate the simultaneous blockade of three immune checkpoint pathways, PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of the's company DNAM axis hypothesis and biomarker strategy ...

Yahoo | September 9, 2020

Compugen launches early-stage combination study for COM701 in solid tumors

Dosing is underway in Compugen's ([[CGEN]] -3.1%) Phase 1/2 study evaluating the triple combination of Compugen's COM701, with Bristol Myers Squibb's Opdivo (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207, for solid tumors.The 100-subject trial is designed to evaluate the safety, tolerability and preliminary antitumor activity of COM701+Opdivo+BMS 986207 combo during dose...

Seeking Alpha | September 8, 2020

Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase 1/2 study evaluating the triple combination of COM701, Compugen's first-in-class anti-PVRIG antibody, with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207.

Yahoo | September 8, 2020

Compugen to Present at Upcoming September 2020 Investor Conferences

Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:

Yahoo | September 3, 2020

Read More 'CGEN' Stories Here

CGEN Price Returns

1-mo -12.32%
3-mo 8.45%
6-mo 127.02%
1-year 281.73%
3-year 340.54%
5-year 222.77%
YTD 173.49%
2019 174.65%
2018 -13.20%
2017 -50.98%
2016 -20.19%
2015 -23.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6654 seconds.